Earnings ·
IDEAYA Biosciences reported second quarter 2026 financial results on August 4, 2026
IDYAIDEAYA Biosciences, Inc.
IDEAYA Biosciences reported second quarter 2026 financial results on August 4, 2026. The company announced that its registrational OptimUM-02 trial for darovasertib in metastatic uveal melanoma met its primary endpoint, showing a median progression-free survival of 6.9 months versus 3.1 months for the control arm (HR: 0.42). An NDA filing is underway under the FDA's real-time oncology review program, with completion expected in H2 2026. Financially, collaboration revenue was $8.9 million, R&D expenses were $108.7 million, and net loss was $112.5 million. The company holds approximately $1.24 billion in cash following a June equity offering that raised $323.4 million. IDEAYA Biosciences operates in the biotechnology industry, focusing on the discovery and development of precision medicine oncology therapies.